9/12/2018
Reuters story on kidney cancer drug makes us ask: How is this journalism?
4/17/2018
Immunotherapy prolongs survival, but at what cost? Washington Post needed more on treatment downsides
4/17/2018
Without any independent sources providing insight, readers of TIME’s coverage on lung cancer immunotherapy mostly left in the dark
10/24/2017
Washington Post wisely quantifies severe side effects and deaths from CAR-T cell therapy
9/21/2017
AP’s story on cancer immunotherapy quickly mentions low success rate
7/18/2017
Washington Post wisely notes that CAR T-cell therapy may cost at least $300,000
7/13/2017
It’s misleading to call results from phase 1 trials with 6 and 13 patients a ‘cancer breakthrough’
6/1/2017
Immunotherapy’s ‘new era:’ LA Times story overlooks the risks and overstates trial results
5/22/2017
Keytruda for bladder cancer: No independent scrutiny of Merck-reported results
4/4/2017
‘Promising’ new lymphoma treatment gets superficial, one-sided coverage by CBS
